UniQure Secures $175 Million Loan Facility to Support AMT-130 Gene Therapy Launch for Huntington's Disease
核心洞察
UniQure entered into a $175 million non-dilutive senior secured term loan facility with Hercules Capital to enhance financial flexibility ahead of AMT-130's potential commercial launch.
The facility consists of three tranches with improved interest rates of 9.70% compared to the previous 11.95%, extending debt maturity from January 2027 to October 2030.
AMT-130 is UniQure's investigational gene therapy for Huntington's disease (搜索), with a potential U.S. commercial launch anticipated in 2026.
UniQure N.V., a leading gene therapy company, announced it has secured a $175 million non-dilutive senior secured term loan facility with specialty finance company Hercules Capital, Inc. The financing is designed to strengthen the company's financial position ahead of the potential commercial launch of AMT-130, its investigational gene therapy for Huntington's disease (搜索).
The transaction provides significant improvements to UniQure's capital structure, extending the maturity of existing debt from January 2027 to October 2030 while reducing borrowing costs. The new facility carries a floating interest rate of 9.70%, representing a substantial decrease from the previous rate of 11.95%.
Financing Structure and Terms
The loan facility is structured in three tranches to provide flexibility based on development milestones. The first tranche consists of $50 million to refinance existing debt at closing. A second tranche of $100 million becomes available upon achieving both a regulatory milestone for AMT-130 and a financial milestone. An additional third tranche of up to $25 million may be accessed subject to Hercules Capital's approval.
All tranches carry a floating interest rate equal to the greater of 9.45% and the prime rate plus 2.45%, currently resulting in a 9.70% rate. The improved terms reflect enhanced confidence in UniQure's development pipeline and commercial prospects.
"This non-dilutive financing keeps funds from the outstanding $50 million debt available until 2030 and provides access to an additional $125 million," said Christian Klemt, chief financial officer of UniQure. "We believe this transaction enhances our financial flexibility to fund the potential commercial launch of AMT-130 in the United States, anticipated in 2026."
AMT-130 Development Program
AMT-130 represents UniQure's lead investigational gene therapy for the treatment of Huntington's disease (搜索), a devastating neurodegenerative disorder. The company anticipates a potential commercial launch in the United States in 2026, positioning this financing to support critical pre-launch activities and initial commercialization efforts.
The timing of the financing aligns with UniQure's broader gene therapy portfolio, which has already achieved regulatory success with the approval of its hemophilia B (搜索) gene therapy. This historic achievement, based on more than a decade of research and clinical development, represents a major milestone in genomic medicine and establishes UniQure's capabilities in bringing gene therapies to market.
Market Response and Strategic Positioning
Following the announcement, UniQure shares increased by approximately 3.15% to $14.09 in pre-market trading on the Nasdaq, reflecting investor confidence in the financing terms and commercial prospects. Hercules Capital shares also gained 0.37% to $19.24 on the New York Stock Exchange.
Leerink Partners (搜索) served as exclusive financial advisor to UniQure on the term loan financing, facilitating the transaction structure that provides both immediate refinancing benefits and future growth capital access.
The non-dilutive nature of the financing preserves shareholder value while providing the capital necessary to support AMT-130's transition from clinical development to commercial launch. This approach reflects UniQure's strategic focus on maintaining financial flexibility while advancing its pipeline of gene therapies for severe diseases including Huntington's disease (搜索), refractory temporal lobe epilepsy (搜索), ALS (搜索), and Fabry disease (搜索).